var data={"title":"Erythema annulare centrifugum","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Erythema annulare centrifugum</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/contributors\" class=\"contributor contributor_credentials\">M. Tye Haeberle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/contributors\" class=\"contributor contributor_credentials\">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 06, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H2000311349\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erythema annulare centrifugum (EAC) is a chronic, reactive phenomenon of the skin presenting with arcuate or annular patches or thin plaques that frequently exhibit trailing scale (<a href=\"image.htm?imageKey=DERM%2F80998%7EDERM%2F59741%7EDERM%2F110696%7EDERM%2F110700\" class=\"graphic graphic_picture graphicRef80998 graphicRef59741 graphicRef110696 graphicRef110700 \">picture 1A-D</a>). EAC has been reported to occur in association with a wide variety of conditions, including infections, drug exposures, food exposures, autoimmune disease, and malignancy. EAC also may occur in the absence of an identifiable exposure or disease. </p><p>The clinical features, diagnosis, and management of EAC are reviewed here. An overview of cutaneous annular eruptions is provided separately. (See <a href=\"topic.htm?path=approach-to-the-patient-with-annular-skin-lesions\" class=\"medical medical_review\">&quot;Approach to the patient with annular skin lesions&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4268085488\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of EAC is unclear. EAC is thought to be a delayed-type hypersensitivity response to a wide variety of antigens, with the specific trigger dependent upon an underlying disease process or exposure. In support of this hypothesis, cultured lymphocytes from a woman with progesterone-induced EAC exhibited a marked increase in interferon-gamma release upon in vitro exposure to progesterone [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/1\" class=\"abstract_t\">1</a>]. In addition, the rapid response of EAC to the tumor necrosis factor inhibitor <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> described in a case report suggests a delayed-type hypersensitivity reaction pattern [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/2\" class=\"abstract_t\">2</a>].</p><p>In many patients, a specific trigger for EAC cannot be identified. However, numerous reports have cited conditions such as diseases, medication exposures, food exposures, and stress as triggers for EAC [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/3\" class=\"abstract_t\">3</a>]. Data are insufficient to confirm a causative relationship. Case series have yielded the following findings:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study of 66 patients with EAC, 48 (72 percent) had a concomitant disease [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/4\" class=\"abstract_t\">4</a>]. The most common associated disease was cutaneous fungal infection, which accounted for 48 percent of associated diseases. Other associations included other skin diseases (18 percent), internal malignancies (13 percent), and other systemic diseases (21 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective chart review in which 45 of 73 patients with EAC had documentation specifying the presence or absence of associated diseases, 16 patients (36 percent) had documentation of an associated disease, including infections, malignancy, thrombocythemia, rheumatoid arthritis, asthma, and preceding drug reactions [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A retrospective chart review of 39 patients with a histopathologic diagnosis of EAC found that 13 patients (33 percent) developed EAC in association with another disease or medical condition, including cutaneous fungal infection, malignancy, pregnancy, autoimmune disease, and medication use [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/6\" class=\"abstract_t\">6</a>].</p><p/><p class=\"headingAnchor\" id=\"H3258780619\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EAC appears to be an uncommon disorder; however, the prevalence and incidence are unknown. EAC most often occurs in adults but may also occur in children. A review of 66 patients with EAC found ages of onset ranging from 5 to 71 years, with a mean age of onset of 40 years [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/4\" class=\"abstract_t\">4</a>]. EAC in a neonate has been reported [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/7\" class=\"abstract_t\">7</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H1494683739\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EAC can occur anywhere on the body but most commonly develops on the trunk <span class=\"nowrap\">and/or</span> lower extremities. </p><p>EAC typically begins as urticarial or erythematous papules that expand centrifugally over the course of several weeks. The peripheral extension is followed by central clearing, resulting in an annular or arcuate patch or thin plaque (<a href=\"image.htm?imageKey=DERM%2F80998%7EDERM%2F59741%7EDERM%2F110696%7EDERM%2F110700\" class=\"graphic graphic_picture graphicRef80998 graphicRef59741 graphicRef110696 graphicRef110700 \">picture 1A-D</a>). Typically, the outer portion of the advancing edge is slightly raised and erythematous, while the trailing edge has a brawny discoloration with scale. When present, the scale can be described as &quot;trailing scale&quot; [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/8\" class=\"abstract_t\">8</a>]. The annular and arcuate lesions can coalesce to form gyrate or serpiginous patterns. Pruritus is variably present. </p><p>The primary lesion in EAC has been a source of debate. Some authors have separated presentations with superficial scale (EAC or superficial gyrate erythema) from presentations without scale (deep gyrate erythema) [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/9,10\" class=\"abstract_t\">9,10</a>]. In general, these presentations are viewed as different morphologic expressions of the same disease process [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/11\" class=\"abstract_t\">11</a>]. </p><p>There are no laboratory abnormalities directly associated with EAC. However, patients may have laboratory abnormalities related to comorbidities. (See <a href=\"#H4268085488\" class=\"local\">'Etiology'</a> above.)</p><p class=\"headingAnchor\" id=\"H4279270131\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histopathologic findings in EAC vary based upon the clinical presentation. Presentations with superficial scale exhibit a dense perivascular lymphocytic inflammatory infiltrate limited to the superficial dermal vascular plexus. The appearance of the perivascular infiltrate is thought to resemble a coat sleeve. In addition, there may be alterations in the papillary dermis and epidermis, including edema, spongiosis, parakeratosis, hyperkeratosis, and basal layer vacuolization [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/4,9\" class=\"abstract_t\">4,9</a>].</p><p>Presentations without superficial scale most often exhibit a tight perivascular lymphocytic infiltrate of the superficial and deep dermal vascular plexuses. Vasculitic changes are not expected but have been reported [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H2878645183\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinicians experienced in the diagnosis of annular cutaneous eruptions often can make a diagnosis of EAC based upon recognition of the classic clinical presentation (annular, arcuate, gyrate, or serpiginous erythematous plaques or patches), particularly if trailing scale is present. A potassium hydroxide preparation is usually performed to rule out tinea corporis. When necessary (eg, clinician uncertainty regarding the diagnosis or atypical clinical presentation), a biopsy should be performed to exclude alternate diagnoses. Serologic studies are not useful for the diagnosis of EAC. (See <a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures#H4044416\" class=\"medical medical_review\">&quot;Office-based dermatologic diagnostic procedures&quot;, section on 'Potassium hydroxide preparation'</a> and <a href=\"#H4279270131\" class=\"local\">'Histopathology'</a> above.)</p><p class=\"headingAnchor\" id=\"H784929572\"><span class=\"h1\">ADDITIONAL EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although data on the relationship between EAC and underlying disease or exposures are limited, we obtain a medication history, review of systems, and physical examination to identify underlying diseases or exposures that may contribute to EAC. The findings of these investigations guide the need for laboratory studies or other tests. We also ensure that the patient has undergone age-appropriate cancer screenings. (See <a href=\"#H4268085488\" class=\"local\">'Etiology'</a> above.)</p><p class=\"headingAnchor\" id=\"H2413892614\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of EAC includes other cutaneous disorders that may present with annular, erythematous eruptions. (See <a href=\"topic.htm?path=approach-to-the-patient-with-annular-skin-lesions\" class=\"medical medical_review\">&quot;Approach to the patient with annular skin lesions&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythema migrans</strong> &ndash; Erythema migrans results from <em>Borrelia</em> infection acquired through a tick bite. The disorder initially presents as a papule at the site of the bite. Two to 30 days later, a red macule appears at the site of the bite, which expands to form an annular plaque (<a href=\"image.htm?imageKey=DERM%2F65203\" class=\"graphic graphic_picture graphicRef65203 \">picture 2</a>). The plaque may range from 5 to more than 68 centimeters in diameter [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/12\" class=\"abstract_t\">12</a>]. Patients may have associated fatigue and lymphadenopathy. Histopathologically, erythema migrans exhibits nonspecific inflammation, but spirochetes may be evident. Serology can aid in the diagnosis and will differentiate erythema migrans from EAC. (See <a href=\"topic.htm?path=clinical-manifestations-of-lyme-disease-in-adults#H5\" class=\"medical medical_review\">&quot;Clinical manifestations of Lyme disease in adults&quot;, section on 'Erythema migrans'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythema marginatum</strong> &ndash; Erythema marginatum is a manifestation of acute rheumatic fever. Erythema marginatum develops in a minority of patients with acute rheumatic fever and is highly specific for the syndrome [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/13,14\" class=\"abstract_t\">13,14</a>]. Children with acute carditis are the most likely to develop erythema marginatum. The disorder manifests as annular erythematous plaques that appear quickly then fade over the course of hours to several days (<a href=\"image.htm?imageKey=DERM%2F73233\" class=\"graphic graphic_picture graphicRef73233 \">picture 3</a>). The morphology and association with rheumatic fever aid in differentiating erythema marginatum from EAC. (See <a href=\"topic.htm?path=acute-rheumatic-fever-clinical-manifestations-and-diagnosis#H8\" class=\"medical medical_review\">&quot;Acute rheumatic fever: Clinical manifestations and diagnosis&quot;, section on 'Erythema marginatum'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythema gyratum repens (EGR)</strong> &ndash; EGR is characterized by the development of concentric rings of migratory erythematous plaques (<a href=\"image.htm?imageKey=DERM%2F57355%7EONC%2F58124\" class=\"graphic graphic_picture graphicRef57355 graphicRef58124 \">picture 4A-B</a>). The appearance of EGR has been described as &quot;wood grain&quot; [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/15\" class=\"abstract_t\">15</a>]. EGR has a strong association with underlying lung, breast, and esophageal cancer and may precede the diagnosis of cancer by several months. Clinically, EGR tends to involve larger areas of the body than EAC and will migrate at a more rapid pace (1 cm per day). EGR tends to have severe pruritus compared with the variable pruritus seen with EAC. On histopathology, EGR typically does not have the classic tight perivascular lymphocytic infiltrate of EAC [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=cutaneous-manifestations-of-internal-malignancy#H3208263\" class=\"medical medical_review\">&quot;Cutaneous manifestations of internal malignancy&quot;, section on 'Erythema gyratum repens'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythema multiforme</strong> &ndash; Erythema multiforme presents as the abrupt onset of annular, target-like lesions with a predilection for the palms and soles (<a href=\"image.htm?imageKey=DERM%2F57894\" class=\"graphic graphic_picture graphicRef57894 \">picture 5</a>). Vesicles or bullae may arise. Mucosal surfaces also may be involved. Erythema multiforme may be a hypersensitivity reaction to various inciting factors, particularly herpes simplex virus and <em>Mycoplasma pneumoniae</em> infections. Histopathologic differentiation between erythema multiforme and EAC is possible with a skin biopsy. (See <a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-erythema-multiforme\" class=\"medical medical_review\">&quot;Pathogenesis, clinical features, and diagnosis of erythema multiforme&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Granuloma annulare</strong> &ndash; Granuloma annulare is an idiopathic disease that most often manifests as annular plaques without scale (<a href=\"image.htm?imageKey=DERM%2F109887%7EDERM%2F71308\" class=\"graphic graphic_picture graphicRef109887 graphicRef71308 \">picture 6A-B</a>). Granuloma annulare and EAC are easily distinguished on pathology. Granuloma annulare shows an interstitial <span class=\"nowrap\">and/or</span> palisaded histiocytic infiltrate with or without collagen necrobiosis. (See <a href=\"topic.htm?path=granuloma-annulare\" class=\"medical medical_review\">&quot;Granuloma annulare&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Sarcoidosis</strong> &ndash; This multisystem inflammatory condition can present in the skin with innumerable clinical morphologies, including annular plaques. Sarcoidosis is easily distinguished from EAC with a skin biopsy. Patients with sarcoidosis may have additional pulmonary or lymph node involvement. (See <a href=\"topic.htm?path=cutaneous-manifestations-of-sarcoidosis\" class=\"medical medical_review\">&quot;Cutaneous manifestations of sarcoidosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Necrolytic migratory erythema (NME)</strong> &ndash; NME presents as eczematous or psoriasiform plaques (<a href=\"image.htm?imageKey=DERM%2F56367\" class=\"graphic graphic_picture graphicRef56367 \">picture 7</a>). Annular lesions may occur. NME tends to be more erosive than EAC. Patients will have associated weight loss, diarrhea, and other metabolic disturbances secondary to an underlying glucagonoma. The distribution of NME tends to be perioral, perianal, and in the inguinal folds [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/16,17\" class=\"abstract_t\">16,17</a>]. (See <a href=\"topic.htm?path=cutaneous-manifestations-of-internal-malignancy#H28405609\" class=\"medical medical_review\">&quot;Cutaneous manifestations of internal malignancy&quot;, section on 'Necrolytic migratory erythema'</a> and <a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome\" class=\"medical medical_review\">&quot;Glucagonoma and the glucagonoma syndrome&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tinea corporis</strong> &ndash; The annular plaques of tinea corporis often have more scale than EAC (<a href=\"image.htm?imageKey=DERM%2F103984\" class=\"graphic graphic_picture graphicRef103984 \">picture 8</a>). In addition, pruritus tends to be more pronounced. In contrast to the trailing scale of EAC, scale is often on the leading edge in tinea corporis. A potassium hydroxide preparation will show branching hyphae. (See <a href=\"topic.htm?path=dermatophyte-tinea-infections#H23\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;, section on 'Tinea corporis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Urticaria</strong> &ndash; The plaques of urticaria often are more evanescent than those of EAC (<a href=\"image.htm?imageKey=DERM%2F60454\" class=\"graphic graphic_picture graphicRef60454 \">picture 9</a>). Urticarial lesions will present for 8 to 24 hours and then fade, whereas EAC can last weeks to months. The biopsy findings of urticaria are subtle and may show eosinophils or neutrophils scattered around superficial vessels, cells that often are not seen in EAC. (See <a href=\"topic.htm?path=new-onset-urticaria\" class=\"medical medical_review\">&quot;New-onset urticaria&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Cutaneous lupus</strong> <strong>erythematosus </strong>&ndash; Cutaneous lupus erythematosus may show annular lesions with scale; subacute cutaneous lupus erythematosus is the most likely subtype to exhibit this morphology (<a href=\"image.htm?imageKey=DERM%2F55903\" class=\"graphic graphic_picture graphicRef55903 \">picture 10</a>). In contrast to EAC, subacute cutaneous lupus erythematosus has a predilection for sun-exposed skin. Definitive differentiation can be made with a biopsy. (See <a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus\" class=\"medical medical_review\">&quot;Overview of cutaneous lupus erythematosus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Syphilis</strong> &ndash; Annular papulosquamous eruptions may warrant consideration of syphilis. This can easily be ruled out with a rapid plasma reagin (RPR) laboratory test. (See <a href=\"topic.htm?path=syphilis-epidemiology-pathophysiology-and-clinical-manifestations-in-hiv-uninfected-patients\" class=\"medical medical_review\">&quot;Syphilis: Epidemiology, pathophysiology, and clinical manifestations in HIV-uninfected patients&quot;</a> and <a href=\"topic.htm?path=syphilis-screening-and-diagnostic-testing\" class=\"medical medical_review\">&quot;Syphilis: Screening and diagnostic testing&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mycosis fungoides (MF)</strong> &ndash; This type of cutaneous T cell lymphoma can share chronicity and annularity with EAC. Advanced cases of MF may show thicker plaques, nodules, and tumors (<a href=\"image.htm?imageKey=HEME%2F73078\" class=\"graphic graphic_picture graphicRef73078 \">picture 11</a>). Lymphadenopathy may be present. A biopsy can differentiate MF from EAC. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythema papulatum centrifugum (EPC)</strong> &ndash; EPC is a pruritic, sweating-related cutaneous disorder that may be a variant of EAC. Clinically, EPC presents as incomplete annular erythema with numerous peripheral papules on the trunk or proximal extremities. The histologic findings include inflammation around dermal and intraepidermal eccrine ducts, a feature not typically seen in EAC [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/18\" class=\"abstract_t\">18</a>]. </p><p/><p class=\"headingAnchor\" id=\"H3788291855\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Data on treatments for EAC are limited to case reports and case series, leaving uncertainty regarding treatment efficacy. No treatment appears to be uniformly effective, and there is a lack of consensus regarding the best approach to treatment. Our initial approach consists of the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Treatment or removal of potential triggers for EAC </strong>&ndash; Clinical experience suggests that treatment of an associated underlying disease often leads to resolution of EAC. In patients for whom the onset of EAC appears to correlate with drug exposure, we discontinue the associated drug when feasible.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical or intralesional corticosteroids </strong>&ndash; Clinical experience suggests that topical or intralesional corticosteroids can reduce clinical signs of inflammation in EAC but do not typically induce complete remission of EAC. Adult patients can apply a medium- to high-potency (eg, group 2 to 4) topical corticosteroid twice daily to affected skin; low- to medium-potency agents (eg, group 4 to 6) are typically used for children (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>). A typical treatment course is two weeks. If there is no response within four weeks, we discontinue topical corticosteroid treatment. </p><p/><p class=\"bulletIndent1\">Intralesional injection of corticosteroids may also aid in decreasing local lesions, at least temporarily. Typically, <a href=\"topic.htm?path=triamcinolone-drug-information\" class=\"drug drug_general\">triamcinolone</a> acetonide at concentrations of 3 to 5 <span class=\"nowrap\">mg/mL</span> is injected into affected areas; individual injections of approximately 0.1 mL are placed 1 cm apart. Improvement is usually evident within one to two weeks after injection. If there is a partial response, injection can be repeated after four to six weeks. </p><p/><p class=\"bulletIndent1\">Cutaneous atrophy is a potential side effect of long-term topical corticosteroid treatment and can also be seen with higher concentrations of intralesional corticosteroids. (See <a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use#H16\" class=\"medical medical_review\">&quot;General principles of dermatologic therapy and topical corticosteroid use&quot;, section on 'Side effects'</a> and <a href=\"topic.htm?path=intralesional-injection\" class=\"medical medical_review\">&quot;Intralesional injection&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Antipruritic agents </strong>&ndash; Patients with pruritus may achieve symptomatic relief with use of topical antipruritic lotions containing menthol, <a href=\"topic.htm?path=camphor-drug-information\" class=\"drug drug_general\">camphor</a>, or <a href=\"topic.htm?path=pramoxine-drug-information\" class=\"drug drug_general\">pramoxine</a>.</p><p/><p>There are scattered reports describing benefit of antimicrobial therapies. A review of five children treated with oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> for 2 to 14 weeks (including four children concomitantly treated with topical corticosteroids) found improvement in all children, with complete clearance occurring in three patients [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/19\" class=\"abstract_t\">19</a>]. Of note, two children who achieved completed clearance had subsequent relapse of disease. In an uncontrolled study in which eight adults received a two-week course of oral <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, all patients had a marked reduction in lesion size and erythema within two weeks [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/20\" class=\"abstract_t\">20</a>]. Three patients who experienced recurrences responded to a repeat course of erythromycin. In addition, a complete response to oral <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> followed by topical metronidazole is documented in a case report [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/21\" class=\"abstract_t\">21</a>]. </p><p>Other treatments that have appeared beneficial in small numbers of patients include <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/2\" class=\"abstract_t\">2</a>], topical <a href=\"topic.htm?path=calcipotriol-calcipotriene-drug-information\" class=\"drug drug_general\">calcipotriol</a> [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/22\" class=\"abstract_t\">22</a>], and prolonged exposure to sunlight [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H2792151585\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EAC may wax and wane over months to years, but most cases tend to resolve spontaneously [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/4\" class=\"abstract_t\">4</a>]. Peculiar patterns of recurrence on a yearly basis have been described [<a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/24-26\" class=\"abstract_t\">24-26</a>]. Treatment of an associated underlying disease will often accelerate resolution of EAC. (See <a href=\"#H3788291855\" class=\"local\">'Treatment'</a> above.)</p><p class=\"headingAnchor\" id=\"H3722617881\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythema annulare centrifugum (EAC) is an uncommon skin disorder that is postulated to represent a delayed-type hypersensitivity response to a variety of antigens. EAC has occurred in association with a variety of conditions, including diseases, drug exposure, and food exposure. In many patients, an associated condition cannot be identified. (See <a href=\"#H4268085488\" class=\"local\">'Etiology'</a> above and <a href=\"#H3258780619\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>EAC can occur on any cutaneous site but most often develops on the trunk <span class=\"nowrap\">and/or</span> lower extremities. The classic clinical findings are annular erythematous patches or thin plaques that may coalesce to form gyrate or serpiginous patterns (<a href=\"image.htm?imageKey=DERM%2F80998%7EDERM%2F59741%7EDERM%2F110696%7EDERM%2F110700\" class=\"graphic graphic_picture graphicRef80998 graphicRef59741 graphicRef110696 graphicRef110700 \">picture 1A-D</a>). There may be overlying trailing scale. EAC may be asymptomatic or pruritic. (See <a href=\"#H1494683739\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinicians experienced in the diagnosis of cutaneous annular eruptions often can diagnose EAC based upon the physical findings. A potassium hydroxide preparation is usually performed to rule out cutaneous fungal infections. When the diagnosis is uncertain, a biopsy can be performed to confirm the diagnosis. (See <a href=\"#H2878645183\" class=\"local\">'Diagnosis'</a> above and <a href=\"topic.htm?path=approach-to-the-patient-with-annular-skin-lesions\" class=\"medical medical_review\">&quot;Approach to the patient with annular skin lesions&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Data on the treatment of EAC are limited, and there is no uniformly effective therapy. Clinical experience suggests that EAC can improve upon treatment of an associated underlying disease or removal of an associated exposure; therefore, we routinely evaluate patients with EAC for underlying disease and other potential triggers. We treat associated underlying disease when it is feasible. (See <a href=\"#H3788291855\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who desire improvement in the appearance of EAC, we suggest topical or intralesional corticosteroids as initial treatment (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Antipruritic agents are useful for managing pruritus. Oral antimicrobial drugs and other agents have been reported to improve EAC in small numbers of patients. (See <a href=\"#H3788291855\" class=\"local\">'Treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/1\" class=\"nounderline abstract_t\">Halevy S, Cohen AD, Lunenfeld E, Grossman N. Autoimmune progesterone dermatitis manifested as erythema annulare centrifugum: Confirmation of progesterone sensitivity by in vitro interferon-gamma release. J Am Acad Dermatol 2002; 47:311.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/2\" class=\"nounderline abstract_t\">Minni J, Sarro R. A novel therapeutic approach to erythema annulare centrifugum. J Am Acad Dermatol 2006; 54:S134.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/3\" class=\"nounderline abstract_t\">Ibrahim SF, Pryor J, Tausk FA. Stress-induced erythema annulare centrifugum. Dermatol Online J 2009; 15:15.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/4\" class=\"nounderline abstract_t\">Kim KJ, Chang SE, Choi JH, et al. Clinicopathologic analysis of 66 cases of erythema annulare centrifugum. J Dermatol 2002; 29:61.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/5\" class=\"nounderline abstract_t\">Weyers W, Diaz-Cascajo C, Weyers I. Erythema annulare centrifugum: results of a clinicopathologic study of 73 patients. Am J Dermatopathol 2003; 25:451.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/6\" class=\"nounderline abstract_t\">Kim DH, Lee JH, Lee JY, Park YM. Erythema Annulare Centrifugum: Analysis of Associated Diseases and Clinical Outcomes according to Histopathologic Classification. Ann Dermatol 2016; 28:257.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/7\" class=\"nounderline abstract_t\">Bottoni U, Innocenzi D, Bonaccorsi P, et al. Erythema annulare centrifugum: report of a case with neonatal onset. J Eur Acad Dermatol Venereol 2002; 16:500.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/8\" class=\"nounderline abstract_t\">Nayak SU, Shenoi SD, Prabhu SM. Erythema annulare centrifugum: deep variant with vasculitis like histopathology. Indian J Dermatol 2013; 58:329.</a></li><li class=\"breakAll\">Ackerman A. Histologic Diagnosis of Inflammatory Skin Diseases, Lea and Febiger, Philadelphia 1978. p.231.</li><li class=\"breakAll\">Ackerman AB, Chongchitnant N, Sanchez J, et al. Histologic Diagnosis of Inflammatory Skin Diseases: An Algorithmic Method Based on Pattern Analysis, 2nd ed, Williams and Wilkins, Baltimore 1997. p.347.</li><li class=\"breakAll\">Espana A. Figurate erythemas. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV (Eds), Elsevier Saunders, Philadelphia 2012. Vol 2, p.307.</li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/12\" class=\"nounderline abstract_t\">Feder HM Jr, Abeles M, Bernstein M, et al. Diagnosis, treatment, and prognosis of erythema migrans and Lyme arthritis. Clin Dermatol 2006; 24:509.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/13\" class=\"nounderline abstract_t\">Cann MP, Sive AA, Norton RE, et al. Clinical presentation of rheumatic fever in an endemic area. Arch Dis Child 2010; 95:455.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/14\" class=\"nounderline abstract_t\">Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation 2015; 131:1806.</a></li><li class=\"breakAll\">Burgdorf W. Erythema annulare centrifugum and other figurate erythemas. In: Fitzpatrick's Dermatology in General Medicine, 6th ed, Freedberg IM, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill Companies, Inc., New York 2003. p.977.</li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/16\" class=\"nounderline abstract_t\">Rodr&iacute;guez G, Vargas E, Aba&uacute;nza C, C&aacute;ceres S. Necrolytic migratory erythema and pancreatic glucagonoma. Biomedica 2016; 36:176.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/17\" class=\"nounderline abstract_t\">John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol 2016; 30:2016.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/18\" class=\"nounderline abstract_t\">Ueda C, Makino T, Mizawa M, Shimizu T. Erythema papulatum centrifugum: a sweat-related dermatitis. J Am Acad Dermatol 2013; 69:e103.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/19\" class=\"nounderline abstract_t\">Kruse LL, Kenner-Bell BM, Mancini AJ. Pediatric Erythema Annulare Centrifugum Treated with Oral Fluconazole: A Retrospective Series. Pediatr Dermatol 2016; 33:501.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/20\" class=\"nounderline abstract_t\">Chuang FC, Lin SH, Wu WM. Erythromycin as a Safe and Effective Treatment Option for Erythema Annulare Centrifugum. Indian J Dermatol 2015; 60:519.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/21\" class=\"nounderline abstract_t\">De Aloe G, Rubegni P, Risulo M, et al. Erythema annulare centrifugum successfully treated with metronidazole. Clin Exp Dermatol 2005; 30:583.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/22\" class=\"nounderline abstract_t\">Gniadecki R. Calcipotriol for erythema annulare centrifugum. Br J Dermatol 2002; 146:317.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/23\" class=\"nounderline abstract_t\">Coronel-P&eacute;rez IM, Morillo-And&uacute;jar M. [Erythema annulare centrifugum responding to natural ultraviolet light]. Actas Dermosifiliogr 2010; 101:177.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/24\" class=\"nounderline abstract_t\">Pi&ntilde;ol Aguad&eacute; J, Gimenez Camarasa J, De Moragas JM. [Annually recurring erythema: an unusual variety of centrifugal annular erythema?]. Arch Argent Dermatol 1966; 16:75.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/25\" class=\"nounderline abstract_t\">Janss G, Schmidt K, Gattuso P, et al. An intensive care unit nurse with a recurring annular lesion. Erythema annulare centrifugum (EAC). Arch Dermatol 1992; 128:977, 980.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-annulare-centrifugum/abstract/26\" class=\"nounderline abstract_t\">Mandel VD, Ferrari B, Manfredini M, et al. Annually recurring erythema annulare centrifugum: a case report. J Med Case Rep 2015; 9:236.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 110153 Version 1.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H3722617881\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H2000311349\" id=\"outline-link-H2000311349\">INTRODUCTION</a></li><li><a href=\"#H4268085488\" id=\"outline-link-H4268085488\">ETIOLOGY</a></li><li><a href=\"#H3258780619\" id=\"outline-link-H3258780619\">EPIDEMIOLOGY</a></li><li><a href=\"#H1494683739\" id=\"outline-link-H1494683739\">CLINICAL FEATURES</a></li><li><a href=\"#H4279270131\" id=\"outline-link-H4279270131\">HISTOPATHOLOGY</a></li><li><a href=\"#H2878645183\" id=\"outline-link-H2878645183\">DIAGNOSIS</a></li><li><a href=\"#H784929572\" id=\"outline-link-H784929572\">ADDITIONAL EVALUATION</a></li><li><a href=\"#H2413892614\" id=\"outline-link-H2413892614\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H3788291855\" id=\"outline-link-H3788291855\">TREATMENT</a></li><li><a href=\"#H2792151585\" id=\"outline-link-H2792151585\">PROGNOSIS</a></li><li><a href=\"#H3722617881\" id=\"outline-link-H3722617881\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/110153|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/80998\" class=\"graphic graphic_picture\">- Erythema annulare centrifugum - light skin</a></li><li><a href=\"image.htm?imageKey=DERM/59741\" class=\"graphic graphic_picture\">- Erythema annulare centrifugum - dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/110696\" class=\"graphic graphic_picture\">- Erythema annulare centrifugum on buttocks</a></li><li><a href=\"image.htm?imageKey=DERM/110700\" class=\"graphic graphic_picture\">- Erythema annulare centrifugum on buttocks 2</a></li><li><a href=\"image.htm?imageKey=DERM/65203\" class=\"graphic graphic_picture\">- Erythema migrans - close view</a></li><li><a href=\"image.htm?imageKey=DERM/73233\" class=\"graphic graphic_picture\">- Erythema marginatum</a></li><li><a href=\"image.htm?imageKey=DERM/57355\" class=\"graphic graphic_picture\">- Erythema gyratum repens lesions</a></li><li><a href=\"image.htm?imageKey=ONC/58124\" class=\"graphic graphic_picture\">- Erythema gyratum repens</a></li><li><a href=\"image.htm?imageKey=DERM/57894\" class=\"graphic graphic_picture\">- Erythema multiforme on extremity</a></li><li><a href=\"image.htm?imageKey=DERM/109887\" class=\"graphic graphic_picture\">- Granuloma annulare plaques</a></li><li><a href=\"image.htm?imageKey=DERM/71308\" class=\"graphic graphic_picture\">- Disseminated granuloma annulare - annular lesions</a></li><li><a href=\"image.htm?imageKey=DERM/56367\" class=\"graphic graphic_picture\">- Necrolytic migratory erythema perineum</a></li><li><a href=\"image.htm?imageKey=DERM/103984\" class=\"graphic graphic_picture\">- Tinea corporis plaques</a></li><li><a href=\"image.htm?imageKey=DERM/60454\" class=\"graphic graphic_picture\">- Urticaria annular lesions</a></li><li><a href=\"image.htm?imageKey=DERM/55903\" class=\"graphic graphic_picture\">- Subacute cutaneous lupus - Annular plaques</a></li><li><a href=\"image.htm?imageKey=HEME/73078\" class=\"graphic graphic_picture\">- Mycosis fungoides plaque</a></li></ul></li><li><div id=\"DERM/110153|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-rheumatic-fever-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Acute rheumatic fever: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-annular-skin-lesions\" class=\"medical medical_review\">Approach to the patient with annular skin lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-lyme-disease-in-adults\" class=\"medical medical_review\">Clinical manifestations of Lyme disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-manifestations-of-internal-malignancy\" class=\"medical medical_review\">Cutaneous manifestations of internal malignancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-manifestations-of-sarcoidosis\" class=\"medical medical_review\">Cutaneous manifestations of sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">Dermatophyte (tinea) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use\" class=\"medical medical_review\">General principles of dermatologic therapy and topical corticosteroid use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome\" class=\"medical medical_review\">Glucagonoma and the glucagonoma syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=granuloma-annulare\" class=\"medical medical_review\">Granuloma annulare</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intralesional-injection\" class=\"medical medical_review\">Intralesional injection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=new-onset-urticaria\" class=\"medical medical_review\">New-onset urticaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures\" class=\"medical medical_review\">Office-based dermatologic diagnostic procedures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus\" class=\"medical medical_review\">Overview of cutaneous lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-erythema-multiforme\" class=\"medical medical_review\">Pathogenesis, clinical features, and diagnosis of erythema multiforme</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=syphilis-epidemiology-pathophysiology-and-clinical-manifestations-in-hiv-uninfected-patients\" class=\"medical medical_review\">Syphilis: Epidemiology, pathophysiology, and clinical manifestations in HIV-uninfected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=syphilis-screening-and-diagnostic-testing\" class=\"medical medical_review\">Syphilis: Screening and diagnostic testing</a></li></ul></div></div>","javascript":null}